OnCo
technologiesTechnologyEstablished

Cancer variant knowledgebases and molecular tumour boards

Curated databases that say what each mutation means for treatment, and the expert meetings that use them to decide on therapy.

OncoKB (MSK; FDA-recognised), CIViC (WashU; open, crowd-curated), My Cancer Genome (Vanderbilt), JAX-CKB, COSMIC (Sanger), ClinVar, and cBioPortal supply the evidence layer for precision oncology; molecular tumour boards (institutional, national such as the UK's Genomic MDTs, and virtual services from Roche NAVIFY, Syapse, and Tempus) apply it to patients. Studies show actionable findings in 30-50% of sequenced patients but treatment uptake of only 10-25%, pointing to access and evidence gaps.

Generic schematic · not to scale · placeholder for the diagnostics front
Molecular read-out

How it works

Expert curation of gene-variant-disease-drug evidence into levels (e.g. OncoKB 1-4, R1-R2), exposed by API for lab reporting and decision support.

Strengths
  • Open, citable evidence
  • Regulatory recognition (OncoKB)
Limitations
  • Curation lag and disagreement between sources
  • Sparse evidence for rare variants
  • Tumour-board capacity

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Cancer variant knowledgebases and molecular tumour boards" OR ABSTRACT:"Cancer variant knowledgebases and molecular tumour boards") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cancer variant knowledgebases and molecular tumour boards, not a curated reading list.

Connected

9top